INCYTE CORP

"Audited: No disclosure detected represented 0.0% of total revenue."

"Per XBRL (Segment Reporting - Schedule of Long-Lived Assets by Geographic Areas (Details)): United States represented 93.4% of disclosed total revenue."

"for most of our drug candidates, once our raw materials are produced, we rely on one third-party to manufacture the API, another to make finished drug product and a third to package and label the finished product."

"No product concentration disclosure was detected in the most recent filing parsed."

"Per XBRL (tagged concentration risk): 54.0% credit / accounts-receivable concentration (Customer ABCD and E)."